Negative preclinical results with stealth® nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model
- 27 September 2004
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 100 (1) , 29-40
- https://doi.org/10.1016/j.jconrel.2004.07.019
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor TargetingThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastomaToxicology Letters, 2001
- Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of ChemotherapyCancer Investigation, 2001
- Daunorubicin-Induced Pathology in the Developing Hamster Molar Tooth Germ in VitroCancer Detection Prevention, 1999
- On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistanceCancer Chemotherapy and Pharmacology, 1996
- Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacyJournal of Neurosurgery, 1995
- Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agentsAdvanced Drug Delivery Reviews, 1995
- Clinical Pharmacokinetics of DoxorubicinClinical Pharmacokinetics, 1988
- Degradation of poly (isobutyl cyanoacrylate) nanoparticlesBiomaterials, 1984
- The 9L rat brain tumor: Description and application of an animal modelZeitschrift für Neurologie, 1981